Insulet Corporation (PODD) fair value: what the stock is really worth
As of Nov 4, 2026: fair value (intrinsic value) of Insulet Corporation stock $182, price $165, upside +10.0%, quality 72 out of 100. Rating: fairly valued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range $127.77 – $352.82 · fair‑value band $117.38 – $235.98 · the $165.02 price screens below the $181.52 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow Insulet in your weekly email
Every Wednesday you see whether Insulet is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.
Show moreShow less
The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System.
It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors.
Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Stock analysis
Insulet Corporation (PODD) currently trades at $165.02, while our model-based Fair Value estimate is $181.52, so the stock looks roughly fairly valued today (gap 9.1%).
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of $146.69 per share, and 3 of the 24 models we run sit above the $165.02 price.
Bear case: the Economic Profit group reads lowest at $29.03, and 21 of the 24 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $117.38 (bear) to $235.98 (bull), the price of $165.02 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 72/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Insulet Corporation reported revenue of $2.7B in FY2025 versus $1.1B in FY2021, a compound +25.3%/yr. Reported net income was $247M in FY2025, compounding +95.8%/yr from FY2021. FY2021 was a trough year, so the rate overstates the trend.
Key figures
Market cap $11.5B Large · P/E ratio 31.1 · P/S ratio 3.75 · EPS (TTM) $5.31 · Net margin 12.3% · Return on equity 26.0% · Return on assets (EBIT) 8.2% · Operating margin 16.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 69 out of 100 (low confidence).
What moves the price
The share trades about 52% below its 52-week high and 26% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at 10%, PODD screens cheaper than that median.
Fair Value models
Bear$117.38Fair Value $181.52Bull$235.98
Price $165.02 · Upside +10.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($4.51 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, 3 officers or directors bought shares worth $1.1M, most recently on Aug 21, 2026. Over the same period, one person sold shares worth $59,887. Buying cluster
BuyAshley McEvoyPresident and CEO, Director2× since Feb 20, 2026: 5,400 shares, avg. $220.63$1.2MAug 21, 2026
SaleLuciana BorioDirector418 shares at $143.27$59,887Jun 3, 2026
BuyTimothy C. StonesiferDirector2× since Dec 5, 2025: 3,752 shares, avg. $186.64$700,277Jun 3, 2026
BuyElizabeth H WeathermanDirector3,450 shares at $144.20$497,490Jun 3, 2026
BuyMichael R MinogueDirector2,030 shares at $246.23$499,847Feb 25, 2026
SaleWayne A.I. FrederickDirector1,851 shares at $293.09$542,510Dec 15, 2025
Plus 15 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+30.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.5%
Start year 2020 (pandemic). Over 10 years: +26.2% a year
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+72.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
+89.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+89.7%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.6% → 18%
Growth Forecast
A lot of optimism in the price
The price assumes less growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+18.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+13.3%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +15.7% a year for the price and +10.7% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (93 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Negative
Recent news coverage is more negative than average.
AI conclusion: High gross margins stand out as the main strength while thin public evidence on most moat factors forms the central weakness.
Main risk: Tandem Diabetes Care and Medtronic could introduce their own tubeless patch pumps that take customers from Omnipod systems and force lower prices or margins.
Bull case: Insulet could extend its lead with fully closed-loop AID systems and stronger international growth that outpaces any new rival offerings.
Bear case: If rivals capture significant share with similar tubeless devices while manufacturing problems trigger repeated regulatory actions, Omnipod could lose its market position and face sustained margin pressure.
Insulet posted strong Q2 revenue growth above 23 percent but trimmed its 2026 US Omnipod outlook while lifting the international target amid Type 2 market trends. Our models see the shares as undervalued. Will faster global expansion offset any US slowdown more than the other way around?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 320 stocks
Beats the industry median on 7/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score72 · Top 25%
Fair Value upside+10.0% · Top 25%
Profitability
Return on equity (12 months)26.0% · Top 25%
Return on assets7.8% · Top 25%
Net margin (12 months)12.3% · Above median
Operating margin (12 months)16.2% · Above median
Growth and dividend
Revenue growth (quarter YoY)23.5% · Top 25%
Balance sheet
Debt / equity0.61× · Highest 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Insulet Corporation Fair Value". https://www.fairvalue-calculator.com/stock/PODD
Frequently asked questions
Is Insulet Corporation (PODD) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of $181.52 versus a price of $165.02, about +10% upside (fairly valued).
What is the fair value of PODD?
Our model-based fair value for Insulet Corporation is $181.52 (as of Nov 5, 2026), built from audited fundamentals. The current price: $165.02.
What is the quality score of PODD?
Insulet Corporation has a Quality Score of 72/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Insulet Corporation (PODD)?
Our model-based price target is the fair value of $181.52 (as of Nov 5, 2026) from 24 valuation models. Cautious scenario $117.38, optimistic scenario $235.98. It is a calculation from audited fundamentals, not an analyst target.
What is the Insulet Corporation stock forecast for 2026?
Our models put fair value at $181.52, about +10% upside versus a price of $165.02 (fairly valued). Cautious scenario $117.38, optimistic scenario $235.98. The calculation is refreshed regularly with new filings.
What is the revenue of Insulet Corporation (PODD)?
Insulet Corporation reported trailing-twelve-month revenue of about $3.1B (latest available figure, as of Nov 5, 2026).
What growth is priced into Insulet Corporation (PODD)?
For today's price to be fair in a discounted-cash-flow model, Insulet Corporation would have to grow free cash flow by +18.4 % per year for five years (discount rate 10.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +24.5 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of PODD use?
Our models discount Insulet Corporation at 10.0 %: a base by market capitalisation (mid), damped by beta 1.10, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Insulet Corporation that is +18.4 % per year a year over ten years, using the same discount rate (10.0 %) and the same formula as our fair value.
How much growth has Insulet Corporation (PODD) delivered so far?
Over the past 5 years revenue at Insulet Corporation grew +24.5 % a year. The price currently implies +18.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Insulet Corporation (PODD) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Insulet Corporation (+18.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Insulet Corporation (PODD)?
The free-cash-flow yield on the price is 3.30 %: that much free cash flow Insulet Corporation produces per unit of market value. When it exceeds the discount rate of our models (10.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Insulet Corporation (PODD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Insulet Corporation it is $181.52 per share (as of Nov 5, 2026), against a price of $165.02. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Insulet Corporation stock overvalued or undervalued in 2026?
As of Nov 5, 2026, PODD trades below its calculated fair value: price $165.02, fair value $181.52, a gap of about +10% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PODD?
No. The price is what the market pays today ($165.02); the fair value is what the company's own numbers justify ($181.52). For Insulet Corporation the two are $16.50 per share apart. That gap is exactly why we show both numbers side by side.
How much is Insulet Corporation worth?
The market values Insulet Corporation at about $11.5B (market capitalisation, as of Nov 5, 2026). Per share that is $165.02; our models calculate a fair value of $181.52 per share.
What do the bullish and bearish scenarios say about PODD?
Our models span a range for Insulet Corporation: cautious scenario $117.38, base $181.52, optimistic $235.98 per share (as of Nov 5, 2026, price $165.02). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of PODD?
Insulet Corporation trades at a price-to-earnings ratio of 31.1 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $181.52 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 33.2 (reported for FY2025: 47.2). Median P/E at fiscal year-end, 8 fiscal years (2018 to 2025), reported earnings, FY2018, FY2023, FY2025 ex one-offs: 1,002.8. Other multiples: PEG 3.3, P/B 7.6, P/S 3.8, EV/EBITDA 19.0.
What is the PEG ratio of PODD?
The PEG ratio of Insulet Corporation is 3.31 (P/E divided by earnings growth, as of Nov 5, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Insulet Corporation (PODD)?
Balance-sheet figures for Insulet Corporation (as of Nov 5, 2026): return on equity 26.0%, debt of 0.61 per unit of equity. They feed the Quality Score of 72/100, which measures business quality independently of the share price.
How far is PODD from its 52-week high?
Insulet Corporation trades at $165.02, about 52% below its 52-week high of $346.36 and 26% above the low of $130.47 (as of Nov 4, 2026). Distance from the high says nothing about value: that is what the fair value of $181.52 is for.
Which stocks are comparable to Insulet Corporation?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Insulet Corporation stock attractive at the current price?
The data as of Nov 5, 2026: price $165.02, calculated fair value $181.52 (+10%), Quality Score 72/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PODD calculated?
We run Insulet Corporation through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $181.52, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.6% above its aggregate fair value. Insulet Corporation currently trades 9% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Insulet Corporation (PODD)?
The closing price on Nov 4, 2026 was $165.02. Our model-based fair value is $181.52, about +10% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Insulet Corporation right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range ($117.38 to $235.98) leaves room in how you read the outcome.
Key figures of Insulet Corporation
How large is the market capitalisation of Insulet Corporation (PODD)?
The market capitalisation of Insulet Corporation is $11.5B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Insulet Corporation (PODD)?
The price-to-sales ratio of Insulet Corporation is 3.75 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Insulet Corporation (PODD)?
Earnings per share at Insulet Corporation are $5.31 (price ÷ EPS = P/E 31.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Insulet Corporation (PODD)?
The net margin of Insulet Corporation is 12.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Insulet Corporation (PODD)?
The return on equity (ROE) of Insulet Corporation is 26.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Insulet Corporation (PODD)?
On an EBIT basis the return on assets of Insulet Corporation is 8.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Insulet Corporation (PODD)?
The operating margin of Insulet Corporation is 16.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Insulet Corporation (PODD)?
Revenue at Insulet Corporation is growing +23.5% versus a year earlier (3y avg +27.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Insulet Corporation (PODD)?
Earnings per share at Insulet Corporation are growing +329% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Insulet Corporation (PODD) carry?
The net debt of Insulet Corporation is $335M (fiscal year 2025, ≈ 0.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Insulet Corporation in the live analysis
One click puts Insulet Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 5, 2026